Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,959.60 | 8.60 | 0.10% |
| CAC 40 | 8,154.91 | 15.97 | 0.20% |
| DAX 40 | 25,578.85 | 3.84 | 0.02% |
| Dow JONES (US) | 51,863.69 | 185.14 | -0.36% |
| FTSE 100 | 10,708.33 | 30.68 | -0.29% |
| HKSE | 24,869.94 | 217.81 | -0.87% |
| NASDAQ | 27,244.28 | 122.18 | 0.45% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,856.22 | 19.26 | -0.14% |
| S&P 500 | 7,764.64 | 0.06 | -0.00% |
| S&P/ASX 200 | 8,766.00 | 8.20 | 0.09% |
| SSE Composite Index | 3,943.25 | 8.88 | -0.22% |